Daniel Soffer: ApoA-1 vs HDL-C as Markers of Cardiovascular Risk
Pablo Corral Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Selin Bilgic et al., published in Journal of Clinical Lipidology, adding:
“ApoA-1 versus HDL-C as markers of cardiovascular risk
HDL-C or ApoA-1:which better reflects cardiovascular risk?
A new analysis from nearly 300,000 UK Biobank participants revisits one of the oldest debates in lipidology:
Key findings:
- ApoA-1 and HDL-C showed similarly strong inverse associations with ASCVD risk
- ApoA-1 explained most of the protective signal traditionally attributed to HDL-C
- Triglycerides contributed far less than expected
- HDL biology may still matter more than many currently assume
Interesting message from this paper:
The story of HDL is probably more nuanced than simply saying ‘HDL is not causal.’
Negative HDL-raising trials did not kill the biology.
They only killed simplistic pharmacology.”
Daniel soffer, Associate Professor of Medicine at University of Pennsylvania, shared this post on LinkedIn:
“Pablo Corral, as usual your posts and commentary are brilliant.
Clearly, HDL is important and clearly, we are measuring what it does poorly.
Manipulating its cholesterol content in serum and even how many HDL particles are in circulation is not the secret.
Perhaps we will figure out how to manipulate HDL for good one day beyond eating healthy, exercising regularly, managing sleep and stress.”
Title: ApoA-1 versus HDL-C as markers of cardiovascular risk
Authors: Selin Bilgic, Karol Pencina, Michael Pencina, Line Dufresne, George Thanassoulis, Allan Sniderman

Stay updated with Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM